Trial Profile
Mobilization of CD34+ cells with standard or reduced dose filgrastim after vinorelbine in multiple myeloma patients. A randomized prospecitve single center phase II study. - ONK-USZ-002
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 May 2019
Price :
$35
*
At a glance
- Drugs Filgrastim (Primary)
- Indications Multiple myeloma
- Focus Pharmacodynamics
- Acronyms ONK-USZ-002
- 12 Jul 2012 New trial record